Fighting COVID-19 with milk?


Authors: Elsevier As the COVID-19 pandemic continues to claim lives around the world, dairy scientists may have a surprising role to play. In a new report published in the Journal of Dairy Science, scientists from the University of Michigan (Ann Arbor, MI, USA) and Glanbia PLC Research and Development (Twin Falls, ID, USA) have collaborated to […]

Potential pharmacologic treatments for COVID-19 smell and taste loss: A comprehensive review


Authors: Elnaz Khani,aSajad Khiali,aSamineh Beheshtirouy,a and Taher Entezari-Malekia,b,∗ Eur J Pharmacol. 2021 Dec 5; 912: 174582.Published online 2021 Oct 19. doi:  10.1016/ j.ejphar.2021.174582 PMCID: PMC8524700PMID: 34678243 Abstract The acute loss of taste and smell following COVID-19 are hallmark symptoms that affect 20–85% of patients. However, the pathophysiology and potential treatments of COVID-19 smell and taste loss are not fully understood. We […]

Colchicine: A Possible COVID-19 Long haul Cardiac Therapy


Last Updated: December 16, 2021 Last Updated: December 16, 2021 Colchicine is an anti-inflammatory drug that is used to treat a variety of conditions, including gout, recurrent pericarditis, and familial Mediterranean fever.1 Recently, the drug has been shown to potentially reduce the risk of cardiovascular events in those with coronary artery disease.2 Colchicine has several potential mechanisms of action, […]

The Role of Colchicine in Pericardial Syndromes


Authors: George Lazaros 1, Massimo Imazio 2, Antonio Brucato 3, Charalambos Vlachopoulos 1, Emilia Lazarou 1, Dimitrios Vassilopoulos 4, Dimitris Tousoulis 1PMID: 29336245 DOI: 10.2174/1381612824666180116101823 Curr Pharm Des . 2018;24(6):702-709. doi: 10.2174/1381612824666180116101823. Abstract Background: Colchicine is an old drug originally employed for the treatment of inflammatory disorders such as acute gout and familiar Mediterranean fever. Methods: In the past few decades, colchicine has been at the forefront of the pharmacotherapy of several […]

Colchicine Treatment for Recurrent Pericarditis


A Decade of Experience Authors: Y. Adler, Y. Finkelstein, J. Guindo, A. Rodriguez de la Serna, Y. Shoenfeld, A. Bayes-Genis, A. Sagie, A. Bayes de Luna and D. H. SpodickOriginally published2 Jun 1998 https://doi.org/10.1161/01.CIR.97.21.2183 Circulation. 1998;97:2183–2185 Abstract Background—The most troublesome complication of acute pericarditis is recurrent episodes of pericardial inflammation, occurring in 15% to 32% of cases. The cause of the recurrence is usually […]

Age- and Sex-Specific Incidence of Cerebral Venous Sinus Thrombosis Associated With Ad26.COV2.S COVID-19 Vaccination


Authors: Aneel A. Ashrani, MD, MS1; Daniel J. Crusan, BS2; Tanya Petterson, MS2; et al JAMA Intern Med. 2022;182(1):80-83. doi:10.1001/jamainternmed.2021.6352 Recent reports1–4 suggest a possible association between Ad26.COV2.S (Johnson & Johnson/Janssen) COVID-19 vaccination and cerebral venous sinus thrombosis (CVST). Estimates of postvaccination CVST risk require accurate age- and sex-specific prepandemic CVST incidence rates; however, reported rates vary widely.5 We compared the age- and sex-specific CVST rates after […]

Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities


The I-TECH Randomized Clinical Trial Authors: Steven Chee Loon Lim, MRCP1; Chee Peng Hor, MSc2,3; Kim Heng Tay, MRCP4; et al JAMA Intern Med. Published online February 18, 2022. doi:10.1001/jamainternmed.2022.0189 Key Points Question  Does adding ivermectin, an inexpensive and widely available antiparasitic drug, to the standard of care reduce the risk of severe disease in patients with COVID-19 and comorbidities? Findings  In this open-label randomized clinical trial […]

Management of urticaria in COVID-19 patients: A systematic review


Authors: Eyad Abuelgasim,Ann Christine Modaragamage Dona,Rajan Singh Sondh,Amer Harky First published: 28 September 2020 https://doi.org/10.1111/dth.14328 Abstract The global pandemic COVID-19 has resulted in significant global morbidity, mortality and increased healthcare demands. There is now emerging evidence of patients experiencing urticaria. We sought to systematically review current evidence, critique the literature, and present our findings. Allowing PRISMA […]

Famotidine clinical trial shows COVID-19 symptom reduction


Authors:  Dagnia Zeidlickis, Vice President, Communications | zeidlick@cshl.edu | 516-367-8455 A high dose of famotidine, commonly known as Pepcid®, was found to have beneficial effects in adult patients with coronavirus disease 2019 (COVID-19), according to results of an outpatient clinical trial. Patients who took famotidine in this trial experienced a decrease of inflammation within the body and reported earlier […]

OPINION


Here’s how to detox from the COVID spike protein – from the jab or the virus Spike proteins can circulate in your body after infection or injection, causing damage to cells, tissues and organs, but the World Council for Health has compiled a list of medications to prevent this. Thu Dec 23, 2021 – 10:38 […]